US Tumor Necrosis Factor Alpha Inhibitors Market

ID: MRFR/Pharma/15194-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Tumor Necrosis Factor Alpha Inhibitors Market Research Report By Drug Class (Monoclonal Antibodies, Fusion Proteins, Recombinant Proteins), By Indication (Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis), By Route of Administration (Subcutaneous, Intravenous, Oral) and By End User (Hospitals, Specialty Clinics, Homecare Settings) - Growth & Industry Forecast 2025 To 2035
US Tumor Necrosis Factor Alpha Inhibitors Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.17%
2024 Market Size$ 5.07 Billion
2025 Market Size$ 5.23 Billion
2035 Market Size$ 7.15 Billion
Key Players
AbbVie
Amgen
Johnson & Johnson
Bristol-Myers Squibb
Merck & Co.
Novartis
Trends
  • Rising Demand for Biologics
  • Focus on Personalized Medicine
  • Advancements in Drug Development
Opportunities
  • Rising Healthcare Expenditure
  • Regulatory Support for Biologics
  • Advancements in Clinical Research
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Drug Class (USD Billion)
      1. 4.1.1 Monoclonal Antibodies
      2. 4.1.2 Fusion Proteins
      3. 4.1.3 Recombinant Proteins
    2. 4.2 Security, Access Control and Robotics, BY Indication (USD Billion)
      1. 4.2.1 Rheumatoid Arthritis
      2. 4.2.2 Psoriasis
      3. 4.2.3 Inflammatory Bowel Disease
      4. 4.2.4 Ankylosing Spondylitis
    3. 4.3 Security, Access Control and Robotics, BY Route of Administration (USD Billion)
      1. 4.3.1 Subcutaneous
      2. 4.3.2 Intravenous
      3. 4.3.3 Oral
    4. 4.4 Security, Access Control and Robotics, BY End User (USD Billion)
      1. 4.4.1 Hospitals
      2. 4.4.2 Specialty Clinics
      3. 4.4.3 Homecare Settings
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 AbbVie (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Amgen (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Johnson & Johnson (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Bristol-Myers Squibb (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Merck & Co. (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Novartis (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Roche (CH)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Sanofi (FR)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Pfizer (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY DRUG CLASS
    3. 6.3 US MARKET ANALYSIS BY INDICATION
    4. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 (% SHARE)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY INDICATION, 2024 (% SHARE)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY INDICATION, 2024 TO 2035 (USD Billion)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    17. 6.17 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    18. 6.18 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 (% SHARE)
    19. 6.19 SECURITY, ACCESS CONTROL AND ROBOTICS, BY END USER, 2024 TO 2035 (USD Billion)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion)
      2. 7.2.2 BY INDICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Tumor Necrosis Factor Alpha Inhibitors Market Segmentation

US Tumor Necrosis Factor Alpha Inhibitors Market By Drug Class (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Fusion Proteins
  • Recombinant Proteins

US Tumor Necrosis Factor Alpha Inhibitors Market By Indication (USD Billion, 2025-2035)

  • Rheumatoid Arthritis
  • Psoriasis
  • Inflammatory Bowel Disease
  • Ankylosing Spondylitis

US Tumor Necrosis Factor Alpha Inhibitors Market By Route of Administration (USD Billion, 2025-2035)

  • Subcutaneous
  • Intravenous
  • Oral

US Tumor Necrosis Factor Alpha Inhibitors Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.